Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257033 | 0.88 | NOTUM (0.56) | NOTUMFLT3GSK3BKEAP1NFE2L2 | |
| SCHEMBL2583096 | 0.82 | NOTUM (0.56) | NOTUMFLT3GSK3BKEAP1NFE2L2 | |
| SCHEMBL9634370 | 0.81 | NOTUM (0.50) | NOTUM | |
| SCHEMBL23451552 | 0.81 | NOTUM (0.56) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL5116625 | 0.79 | NOTUM (0.47) | NOTUMFLT3GSK3BSTSRXRA | |
| SCHEMBL31636683 | 0.77 | NOTUM (0.57) | NOTUMFLT3GSK3BKEAP1NFE2L2 | |
| SCHEMBL10290183 | 0.76 | NOTUM (0.60) | NOTUMFLT3GSK3BKEAP1NFE2L2 | |
| SCHEMBL5128529 | 0.75 | NOTUM (0.54) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL27983551 | 0.74 | NOTUM (0.61) | NOTUMFLT3GSK3BKMT2A | |
| SCHEMBL5487663 | 0.73 | KDM5B (0.44) | NOTUMFLT3GSK3BRXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM5, GRM1, GRM2 | NOTUM 3794/4885FLT3 2424/4885GSK3B 4323/4885 |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM2 | NOTUM 3794/4885FLT3 2424/4885GSK3B 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.